Myeloproliferative Neoplasms Biology and Therapy
This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and d
- PDF / 8,669,468 Bytes
- 233 Pages / 498.498 x 688.08 pts Page_size
- 22 Downloads / 212 Views
Srdan Verstovsek Ayalew Tefferi Editors
Myeloproliferative Neoplasms Biology and Therapy
Myeloproliferative Neoplasms
C O N T E M P O R A R Y H E M AT O L O G Y
Judith E. Karp, MD, Series Editor
For other titles published in this series, go to www.springer.com/series/7681
Myeloproliferative Neoplasms Biology and Therapy
Edited by
Srdan Verstovsek The University of Texas M.D. Anderson Cancer Center Houston, TX USA
Ayalew Tefferi Mayo Clinic Rochester, MN USA
Editors Srdan Verstovsek, MD, PhD Department of Leukemia The University of Texas M.D. Anderson Cancer Center Houston, TX USA [email protected]
Ayalew Tefferi, MD Division of Hematology Mayo Clinic Rochester, MN USA [email protected]
Series Editor Judith E. Karp, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Division of Hematologic Malignancies Baltimore, MD
ISBN 978-1-60761-265-0 e-ISBN 978-1-60761-266-7 DOI 10.1007/978-1-60761-266-7 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010937641 © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface
The year 2011 marks the golden anniversary of the first formal description of the classic myeloproliferative neoplasms (MPN) by William Dameshek (1900–1969) [1]. Dr. Dameshek underscored the histologic similarities between polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myelogenous leukemia (CML), and coined the term “myeloproliferative disorders (MPD),” in 1951 [2], to describe them. In 1960, Peter Nowell (1928) and David Hungerford (1927–1993) discovered the Philadelphia chromosome (Ph1) and its invariable association with CML [3]. In 1967, 1976, 1978, and 1981, Philip Fialkow (1934–1996) and colleagues used polymorphisms in the X-linked glucose-6-phosphate dehydrogenase (G-6-PD) locus to establish the stem cell-
Data Loading...
